An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
[HTML][HTML] The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
B Killingley, AJ Mann, M Kalinova, A Boyers… - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
[HTML][HTML] Early remdesivir to prevent progression to severe Covid-19 in outpatients
RL Gottlieb, CE Vaca, R Paredes, J Mera… - … England Journal of …, 2022 - Mass Medical Soc
Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …
to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …
[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …
COVID-19. Outline the latest treatments available in the management of COVID-19 …
[HTML][HTML] Global pandemics interconnected—obesity, impaired metabolic health and COVID-19
Obesity and impaired metabolic health are established risk factors for the non-
communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease …
communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease …
Severe covid-19 pneumonia: pathogenesis and clinical management
AH Attaway, RG Scheraga, A Bhimraj, M Biehl… - bmj, 2021 - bmj.com
Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …
communities. Older age, male sex, and comorbidities increase the risk for severe disease …
COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment
A Parasher - Postgraduate medical journal, 2021 - academic.oup.com
Background The severe acute respiratory syndrome (SARS) coronavirus-2 is a novel
coronavirus belonging to the family Coronaviridae and is now known to be responsible for …
coronavirus belonging to the family Coronaviridae and is now known to be responsible for …
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 …
PD Monk, RJ Marsden, VJ Tear, J Brookes… - The Lancet …, 2021 - thelancet.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
carries a substantial risk of severe and prolonged illness; treatment options are currently …
carries a substantial risk of severe and prolonged illness; treatment options are currently …
COVID-19: Discovery, diagnostics and drug development
T Asselah, D Durantel, E Pasmant, G Lau… - Journal of …, 2021 - Elsevier
Summary Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019,
and has since become a pandemic. Groups from China identified and sequenced the virus …
and has since become a pandemic. Groups from China identified and sequenced the virus …